IRIS
MOSCARELLA, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.362
AS - Asia 1.763
NA - Nord America 1.387
SA - Sud America 372
AF - Africa 31
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 7.917
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 3.342
US - Stati Uniti d'America 1.356
SG - Singapore 628
CN - Cina 454
IE - Irlanda 409
BR - Brasile 310
HK - Hong Kong 303
VN - Vietnam 152
IT - Italia 142
DE - Germania 135
GB - Regno Unito 128
KR - Corea 89
IN - India 51
GR - Grecia 47
SE - Svezia 33
AR - Argentina 32
UA - Ucraina 29
MX - Messico 21
AT - Austria 20
TR - Turchia 19
FI - Finlandia 18
FR - Francia 17
BD - Bangladesh 16
BE - Belgio 14
ID - Indonesia 14
EC - Ecuador 9
ZA - Sudafrica 9
CO - Colombia 7
MA - Marocco 7
CA - Canada 6
ES - Italia 6
IQ - Iraq 6
JP - Giappone 6
NL - Olanda 6
KE - Kenya 5
PK - Pakistan 5
VE - Venezuela 5
EG - Egitto 4
CL - Cile 3
IL - Israele 3
LT - Lituania 3
PL - Polonia 3
UY - Uruguay 3
AM - Armenia 2
BY - Bielorussia 2
DK - Danimarca 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
NO - Norvegia 2
NP - Nepal 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BO - Bolivia 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
GH - Ghana 1
IR - Iran 1
JM - Giamaica 1
JO - Giordania 1
KZ - Kazakistan 1
MU - Mauritius 1
NG - Nigeria 1
PE - Perù 1
PY - Paraguay 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 7.917
Salva come PNG Salva come JPEG
Città #
Moscow 1.156
Dublin 403
Hong Kong 303
Santa Clara 297
Singapore 265
Chandler 212
New York 138
Seoul 89
Hefei 84
Bremen 60
Princeton 58
Roxbury 56
Ho Chi Minh City 55
Beijing 51
The Dalles 47
Medford 43
Jacksonville 42
Ashburn 41
Boardman 30
Bengaluru 29
Naples 28
Hanoi 27
Des Moines 24
Dallas 23
São Paulo 23
Nuremberg 21
Falkenstein 18
Los Angeles 18
Rio de Janeiro 18
Cambridge 15
Wilmington 15
Brussels 14
Jinan 14
Nanjing 14
Hyderabad 11
Caserta 10
Ann Arbor 9
Brasília 9
Helsinki 9
Munich 9
Vienna 9
Aversa 8
Belo Horizonte 8
Guangzhou 8
Sivas 8
Zhengzhou 8
Da Nang 7
Hangzhou 7
Mexico City 7
Shenyang 7
Stockholm 7
Hebei 6
Johannesburg 6
Ninh Bình 6
Rome 6
Boston 5
Changsha 5
Columbus 5
Curitiba 5
Ercolano 5
Guayaquil 5
Haiphong 5
Houston 5
Joinville 5
Nairobi 5
Tianjin 5
Woodbridge 5
Campinas 4
Dhaka 4
Lappeenranta 4
London 4
Malang 4
Milan 4
Shanghai 4
Bari 3
Biên Hòa 3
Bogotá 3
Bologna 3
Boone 3
Carapicuíba 3
Casablanca 3
Casier 3
Chennai 3
Columbia 3
Düsseldorf 3
Frankfurt am Main 3
Goiânia 3
Haikou 3
Istanbul 3
Itaquaquecetuba 3
Lanzhou 3
Lấp Vò 3
Marano Di Napoli 3
Montevideo 3
Ningbo 3
Paris 3
Phủ Lý 3
Porto Alegre 3
Praia Grande 3
Qingyuan 3
Totale 4.062
Salva come PNG Salva come JPEG
Nome #
Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy 155
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 145
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 144
Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: Results from a multicenter Italian experience. 143
Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study) 140
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 137
Childhood obesity: An overview of laboratory medicine, exercise and microbiome 136
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 130
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A contemporary reappraisal 127
Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study 127
Clinical findings after bioresorbable vascular scaffold implantation in an unrestricted cohort of patients with ST-segment elevation myocardial infarction (from the RAI registry) 126
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 118
Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions 115
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 115
Bioresorbable Vascular Scaffolds in In-Stent Restenosis 114
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 113
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 113
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 111
Bioabsorbable drug-eluting vascular scaffold for the treatment of coronary in-stent restenosis: A two center registry 110
Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry 109
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. 107
Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation? 105
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 103
Pathophysiology, Functional Assessment and Prognostic Implications of Nutritional Disorders in Systemic Amyloidosis 102
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 102
Hypertrophic Cardiomyopathy in RASopathies: Diagnosis, Clinical Characteristics, Prognostic Implications, and Management 100
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 100
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 100
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy 97
Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease 97
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 96
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 96
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention 95
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 95
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 94
One-Year Clinical Outcomes After Unrestricted Implantation of Absorb Bioresorbable Scaffold (RAI Registry) 94
Annular size and interaction with trans-catheter aortic valves for treatment of severe bicuspid aortic valve stenosis: Insights from the BEAT registry 94
null 93
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 92
Thirty-Day Outcomes After Unrestricted Implantation of Bioresorbable Vascular Scaffold (from the Prospective RAI Registry) 92
Comparing two-year outcomes of balloon-expandable Myval and self-expanding Evolut R in severe aortic valve stenosis 91
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 91
Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents: Insights of the TROFI II Trial 88
One-year clinical performance of ABSORB bioresorbable vascular scaffold in patients presenting with acute coronary syndromes: Results from the RAI registry 86
Alternative Approaches for Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: The Call for a Personalized Treatment 82
Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions 82
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 82
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 81
IntravaScular Lithotripsy for the Management of UndILatable Coronary StEnt: The SMILE Registry 80
QFR for the Revascularization of Nonculprit Vessels in MI Patients: Insights From the FIRE Trial 78
Severely calcified coronary artery lesions: focus on interventional management 78
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes 78
Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies 78
Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) 77
One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry 77
Methods to assess bioresorbable vascular scaffold devices behaviour after implantation 77
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk 77
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination 77
Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: Insights from five-year follow-up of the EXAMINATION trial 76
Latest STEMI treatment: a focus on current and upcoming devices 75
Multi-step percutaneous treatment of post-myocardial infarction ventricular septal defects: A case report and review of literature 74
Incremental value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy 74
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events 74
Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial) 73
Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis undergoing trans-catheter valve replacement with new generation devices: Insight from the BEAT international collaborative registry 72
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice 71
Sex-Related Differences in Long-Term Outcomes After Early-Onset Myocardial Infarction 71
Management of high and intermediate-high risk pulmonary embolism: A position paper of the Interventional Cardiology Working Group of the Italian Society of Cardiology 71
Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome 70
Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST–Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation 69
New percutaneous interventions in heart failure 68
Long-term outcomes of early-onset myocardial infarction with non-obstructive coronary artery disease (MINOCA) 67
Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology 66
Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism 66
In-stent restenosis because of nickel hypersensitivity: A bioresorbable solution? 65
Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: Insights from the multicentre registro absorb italiano (RAI registry) 64
SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI) 63
First-in-man demonstration of complete bioresorbable vascular scaffold resorption after treatment of in-stent restenosis 63
Long-term clinical outcomes after bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis 63
Meta-Analysis Comparing Outcomes After Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients with Acute Coronary Syndromes 63
Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience 62
Pathophysiology and Treatment of the No-Reflow Phenomenon in ST-Segment Elevation Myocardial Infarction: Focus on Low-Dose Fibrinolysis during Primary Percutaneous Intervention 62
How should I treat a bioresorbable vascular scaffold edge restenosis and intra-scaffold dissection? 62
Letter regarding "hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI" 60
Three-year results of ST-segment elevation myocardial infarction patients treated with a prespecified bioresorbable vascular scaffold implantation strategy: bVS STEMI STRATEGY-IT long-term 60
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 59
Time for implementing high-sensitivity cardiac troponin assays in emergency departments in Italy 58
Sudden cardiac death after early-onset myocardial infarction: a multicentre longitudinal cohort study with a 20-year follow-up 57
Five-year clinical outcomes of STEMI patients treated with a pre-specified bioresorbable vascular scaffold implantation technique: Final results of the BVS STEMI STRATEGY-IT 57
Outcomes of 10,312 patients treated with everolimus-eluting bioresorbable scaffolds during daily clinical practice – results from the European Absorb Consortium 50
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects 41
Totale 8.088
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.115
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.115
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021102 0 0 0 0 0 0 37 2 2 7 48 6
2021/2022385 5 0 0 17 121 9 5 31 8 27 28 134
2022/2023777 93 58 12 50 108 35 3 34 356 1 11 16
2023/2024465 20 8 9 11 99 137 27 0 3 17 21 113
2024/20251.293 2 21 5 49 194 156 190 122 165 199 118 72
2025/20264.817 215 282 334 329 486 3.171 0 0 0 0 0 0
Totale 8.088